Would you consider a treatment holiday in a patient with HR+ oligometastatic breast cancer who is in a prolonged remission?

Obviously, we have little data to guide our approach here. However, I would feel a bit uncomfortable holding the patient's AI but would consider it in certain situations, such as the patient having toxicities that are difficult to tolerate. In that situation, I would consider an alternative endocrin...

I agree with the fact that there is little evidence to guide medical decision making in this particular case. This would constitute an ideal case whereby circulating tumor DNA could potentially inform medical decision-making.
The dichotomy between metastatic versus nonmetastatic disease is seriously ...

If she is tolerating treatment and has no complications from it, I would continue. If she has significant side effects and wanted to stop, I think that would be completely reasonable.

I do agree with @Dr. First Last that sometimes getting surveillance imaging covered in these cases can be challengin...